目标试验模拟与随机对照试验的一致性:系统综述与荟萃分析
该系统综述与荟萃分析纳入107对目标试验模拟与基准随机对照试验配对,评估两者结果一致性。总体Pearson相关系数为0.59(95%CI 0.45至0.70),标准化差异一致率为79%(85/107),汇总比值比为0.96(95%CI 0.92至1.01)。设计更接近的63对中一致性更高,相关系数0.83(0.73至0.89),一致率87%(55/63)。
要点
- 目标试验模拟与随机对照试验总体一致性中等,设计更接近时一致性提高。
- 静脉血栓栓塞和主要不良心血管事件结局中模拟倾向于低估效应,呼吸结局中高估。
- 基于理赔数据的模拟倾向于低估治疗效应(比值比0.90,95%CI 0.82至0.99)。
核心结论
- 当前目标试验模拟在复现对应随机对照试验时达到中等一致性。
- 通过更好的模拟设计(包括基线和结局模拟及多源链接数据库)可提高一致性。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、EMBASE、Scopus、PsycINFO和Web of Science(2010至2025年)。
- 纳入明确旨在模拟健康干预目标随机对照试验的观察性研究,共107对目标试验模拟-随机对照试验配对。
- 对21项预设模拟设计特征评估一致性,采用Pearson相关系数、标准化差异一致率和比值比,并进行亚组和回归分析。
主要发现
- 107对配对的Pearson相关系数为0.59(95%CI 0.45至0.70),标准化差异一致率为79%(85/107),汇总比值比为0.96(95%CI 0.92至1.01;I2=36%)。
- 63对设计更接近的配对中,Pearson相关系数为0.83(0.73至0.89),标准化差异一致率为87%(55/63)。
- 静脉血栓栓塞结局汇总比值比为0.76(0.58至1.00;I2=40%),主要不良心血管事件为0.91(0.86至0.96;I2=32%),呼吸结局为1.20(1.03至1.40;I2=40%)。
- 基于理赔数据的模拟汇总比值比为0.90(0.82至0.99;I2=38%)。
- 单变量回归分析中,基线人群特征不平衡、治疗在医院开始和结局模拟质量较低与较差的一致性相关。
临床怎么用
- 解读目标试验模拟结果时需考虑其与随机对照试验的一致性仅为中等,尤其特定结局和理赔数据来源时。
- 设计目标试验模拟时应注重基线人群平衡、结局模拟质量和多源链接数据库的使用以提高一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the concordance of results between paired target trial emulations and their benchmarking randomised controlled trials and to explore determinants of emulation success. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, EMBASE, Scopus, PsycINFO, and Web of Science (2010 to 2025). STUDY SELECTION: Observational studies that explicitly aimed to emulate target randomised controlled trials of a health intervention were included. DATA EXTRACTION: Data were extracted on study domain, target population, intervention, comparator, and main outcomes for each emulation and corresponding randomised controlled trial. MAIN OUTCOME MEASURES: For 21 predefined emulation design features, concordance was assessed using Pearson correlation coefficients, standardised difference agreement, and ratio of ratios, with subgroup and regression analyses of study characteristics and concordance. RESULTS: Among 107 target trial emulation-randomised controlled trial pairs, the Pearson correlation coefficient was 0.59 (95% confidence interval (CI) 0.45 to 0.70), standardised difference agreement was 79% (85/107), and summary ratio of ratios was 0.96 (95% CI 0.92 to 1.01; I2=36%). In 63 pairs with closer emulation of trial design, a higher level of agreement was observed, with a Pearson correlation coefficient of 0.83 (0.73 to 0.89) and standardised difference agreement of 87% (55/63). In subgroup analysis, trial emulations tended to systematically underestimate treatment effects from randomised controlled trials for specific outcomes related to venous thromboembolism and major adverse cardiovascular events, while overestimating those for respiratory outcomes, with pooled ratio of ratios of 0.76 (0.58 to 1.00; I2=40%), 0.91 (0.86 to 0.96; I2=32%), and 1.20 (1.03 to 1.40; I2=40%), respectively. Moreover, emulations based on claims data tended to underestimate the treatment effects (ratio of ratios 0.90, 0.82 to 0.99; I2=38%). In univariate regression analyses, poorer target trial emulation-randomised controlled trial concordance was associated with emulation designs with imbalanced baseline population characteristics, treatment started in hospital, and lower outcome emulation quality. CONCLUSIONS: Current target trial emulations achieve moderate concordance when replicating their corresponding randomised controlled trials. Concordance could be improved by better emulation design, including better baseline and outcome emulation and leveraging multisource linked databases. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024619811.
引用
- Wang C, Tang D, von Dadelszen P, et al. Concordance between target trial emulation and randomised controlled trials: systematic review and meta-analysis. BMJ. 2026. PMID: 42156120. doi:10.1136/bmj-2025-086810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。